Skip to main content
TAGS

Founder Five in 5: Tui Biologics

Meet the team behind the University of Waikato's Tui Biologics: Dr Will Kelton, Antibody Biology/protein engineering; Dr Kyrin Hanning, Bioinformagician/library design; and Patrick Wightman, Screening platform development. The team make up one of the 22 ventures participating in the Sprout Accelerator Spring26 Cohort.

We caught up with Tui Biologics for a quick-fire five questions in five minutes to learn more about their venture and what they hope to achieve from their time in the Sprout Accelerator. 

1. Tell us about Tui Biologics. What are you building?

Companion animals represent one of the fastest growing sectors for biological antibody drugs, especially for the treatment of complex diseases. 

Further improving these therapeutics to enhance efficacy and reduce dosing frequency can be achieved by making precise changes to the protein structure, but identifying where to make these changes remains a challenge. 

While developing enhanced vaccines for livestock, we created a new protein engineering platform that blends the collection of experimental data with AI models to discover new variants. We are now applying our approach to the companion animal space to develop a new generation of functional antibodies.


2. What problem are you working to solve? 

A key issue with biological drugs for companion animals is the required dosing frequency. 

Although some antibodies require only monthly injections, these remain costly and challenging for owners trying to maintain compliance with required dosing regimens over an animal’s lifetime. Extending dosing to every 3-6 months would alleviate many of these issues. 

Beyond the issue of antibody half-life some antibody therapeutics have undesirable side effects that limit drug efficiency, such as immune responses against the drug itself. 


3. How does your solution work? 

Using AI assistance, our technology enables the efficient searching of antibody sequences to find variants that would be very difficult to find by conventional means. By exploring many orders of magnitude more solutions to a given antibody problem, we can aid our customers by developing tailored therapeutics with improved pharmacokinetic profiles. 

Our approach can also assist with improving efficacy at lower doses, thus reducing the chance of side effects.


4. What is the next important milestone for your venture? 

Having established technical proof of concept with antibody variants derived from ruminants, our next milestone is to demonstrate a high-performing variant from a companion animal species. These variants will pave the way for in vivo trialling.

5. What are you hoping to get out of your time with Sprout? 

We are aiming to build knowledge and capability on the business side of the company, all while building connections with current animal industry leaders. As part of this development, we would like to get strong market validation to define specific antibody drug targets for which our approach would have maximal benefit. Finally, we would like to ensure we understand the current IP landscape to ensure our variants have a clear path to development without being encumbered by existing IP.